1. |
Lopez-Herrera G, Tampella G, Pan-Hammarstrom Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet, 2012, 90(6): 986-1001.
|
2. |
Xu C, Min J. Structure and function of WD40 domain proteins. Protein Cell, 2011, 2: 202-214.
|
3. |
Alkhairy OK, Abolhassani H, Rezaei N, et al. Spectrum of phenotypes associated with mutations in LRBA. J Clin Immunol, 2016, 36(1): 33-45.
|
4. |
Gámez-Díaz L, August D, Stepensky P, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol, 2016, 137(1): 223-230.
|
5. |
Moser von Filseck J, Čopič A, Delfosse V, et al. INTRACELLULAR TRANSPORT. Phosphatidylserine transport by ORP/Osh proteins is driven by phosphatidylinositol 4-phosphate. Science, 2015, 349(6246): 432-436.
|
6. |
Lenardo M, Lo B, Lucas CL, et al. Genomics of immune diseases and new therapies. Annu Rev Immunol, 2016, 34(1): 121-149.
|
7. |
Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med, 2014, 20(12): 1410.
|
8. |
Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. J Allergy Clin Immun, 2018, 142(6): 1932-1946.
|
9. |
中华医学会儿科学分会呼吸学组全国儿童弥漫性肺实质疾病/肺间质疾病协作组. 儿童肺间质疾病诊断程序专家共识. 中华儿科杂志, 2013, 51(2): 101-102.
|
10. |
Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society Clinical Practice Guideline: Classification, Evaluation, and Management of Childhood Interstitial Lung Disease in Infancy. Am J Respir Crit Care Med, 2013, 188: 376-394.
|
11. |
Serwas NK, Kansu A, Santos-Valente E, et al. Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflamm Bowel Dis, 2015, 21(1): 40-47.
|
12. |
Bal SK, Haskologlu S, Serwas NK, et al. Multiple presentations of LRBA deficiency: a single-center experience. J Clin Immunol, 2017, 37(8): 790-800.
|
13. |
Schussler E, Beasley MB, Maglione PJ. Lung disease in primary antibody deficiencies. J Allergy Clin Immunol Pract, 2016, 4(6): 1039-1052.
|
14. |
Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science, 2015, 349(6246): 436-440.
|
15. |
Kiykim A, Ogulur I, Dursun E, et al. Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract, 2019, 7(8): 2790-2800.
|